R. Alan B. Ezekowitz

Co-Founder at Vividion Therapeutics, Inc.

R. Alan B. Ezekowitz

R. Alan B. Ezekowitz

Co-Founder at Vividion Therapeutics, Inc.

Overview
Career Highlights

Vividion Therapeutics, Inc.
Abide Therapeutics, Inc.
Azanta Danmark A/S

RelSci Relationships

2462

Number of Boards

14

Birthday

1954

Age

65

Relationships
RelSci Relationships are individuals R. Alan B. Ezekowitz likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Cardinal Partners

Relationship likelihood: Strong

Chairman, Department of Chemical Physiology at The Scripps Research Institute

Relationship likelihood: Strong

Co-Founder at REPLIGEN Corp.

Relationship likelihood: Strong

Co-Founder at Abide Therapeutics, Inc.

Relationship likelihood: Strong

Venture Partner at ARCH Venture Partners

Relationship likelihood: Strong

Chief Executive Officer at Kallyope, Inc.

Relationship likelihood: Strong

Medical Director of Clinical & Quality Analysis at Partners HealthCare System, Inc.

Relationship likelihood: Strong

Venture Partner at ARCH Venture Partners

Relationship likelihood: Strong

Co-Founder at Vividion Therapeutics, Inc.

Relationship likelihood: Strong

President & Chief Operating Officer at Abide Therapeutics, Inc.

Relationship likelihood: Strong

Paths to R. Alan B. Ezekowitz
Potential Connections via
Relationship Science
You
R. Alan B. Ezekowitz
Co-Founder at Vividion Therapeutics, Inc.
Education
Doctor of Philosophy

Oxford is a collegiate university, consisting of the central University and colleges. The central University is composed of academic departments and research centres, administrative departments, libraries and museums. The 38 colleges are self-governing and financially independent institutions, which are related to the central University in a federal system. There are also six permanent private halls, which were founded by different Christian denominations and which still retain their Christian character.

Career History
Co-Founder
2014 - Current

Vividion Therapeutics, Inc. operates as a biotechnology company. It focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke andAlan Ezekowitz in 2014 and is headquartered in Princeton, NJ.

Co-Founder
2011 - Current

Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA.

Venture Partner
2011 - Current

Cardinal Partners invests in life sciences, medical devices and healthcare information technology. The firm provides financing for early-stage companies with an investment size of $6 million to $12 million. It leads initial round of investment.

Boards & Committees
Director
2017 - Current

Fulcrum Therapeutics, Inc. develops new medicines. It focuses on unlocking gene control mechanisms to develop small molecule therapies. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein in July 2016 and is headquartered in Cambridge, MA.

Member, Advisory Board
Current

Qpid Health, Inc. provides health record acceleration software and intelligence solutions. It develops clinical insights software for use by hospitals and medical groups. The firm's QPID solution uses natural language processing and proprietary tools to improve how clinical and administrative users can have access to information stored in electronic health records. The company was founded by Michael Zalis and Mitchell Harris in 2011 and is headquartered in Boston, MA.

Chief Executive Officer & Director
Current

Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA.

Chairman
Prior

Massachusetts General Hospital Cancer Center operates as cancer treatment center. The company was founded by John Warren in 1811 and is headquartered in Boston, MA.

Member, Board of Directors
Prior

Children's Hospital Corp. provides health care services that includes acupuncture, cardiac anesthesia, pediatric cataract, andrology program, atopic dermatits center, augmentative communication program, exercise physiology, endodontics, and many more. The company was founded in 1869 and is headquartered in Boston, MA.

Director
Prior

Partners HealthCare System, Inc. provides patient care, research, teaching and community services. It offers community and specialty hospitals, physician network, community health centers, home care and other health-related entities. The firm also sponsors research programs and community health outreach programs. The company was founded in 1994 and is headquartered in Boston, MA.

Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
$250 - $499
2006

TO CHALLENGE AND NURTURE URBAN YOUTH AS STUDENTS, ATHLETES AND CITIZENS SO THAT THEY RECOGNIZE AND FULFILL THEIR FULLEST POTENTIAL IN LIFE.

Transactions
Details Hidden

Abide Therapeutics, Inc. raised money in a private placement transaction

Investments
Details Hidden

Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA.

Details Hidden

Azanta Danmark A/S operates as biopharmaceutical company developing treatments for women's health indications and for orphan oncology. The firm develops protein therapeutics within oncology and infectious diseases. The company was founded by Martin N. Bonde, Jens Christian Jensenius, Steffen Thiel, and R. Alan B. Ezekowitz in 2000 and is headquartered in Valby, Denmark.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by R. Alan B. Ezekowitz. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of R. Alan B. Ezekowitz's profile does not indicate a business or promotional relationship of any kind between RelSci and R. Alan B. Ezekowitz.
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/person/alan-ezekowitz-3846941
  • https://relationshipscience.com/person/alan-ezekowitz-3846941